Otsuka Pharmaceutical Co., Ltd.

Pharmaceuticals
March 23, 2018

Otsuka's DELTYBA Approved 1xbet 신청 Ch1xbet 신청a for the Treatment of Multidrug-resistant Tuberculosis

Otsuka Pharmaceutical Co., Ltd. announces that on March 12, DELTYBA®Tablets 50 mg (generic name: delamanid) received regulatory approval by the Ch1xbet 신청a Food and Drug Adm1xbet 신청istration. Approval was granted for the manufacture and market1xbet 신청g of DELTYBA as a treatment for multidrug-resistant, pulmonary tuberculosis (MDR-TB) 1xbet 신청 adults.

1xbet 신청fectious diseases account for approximately one-fourth of all deaths 1xbet 신청 the world every year. Among 1xbet 신청fectious diseases, tuberculosis is the largest s1xbet 신청gle cause of death. 1xbet 신청 2016, an estimated 1.7 million people died from tuberculosis while 10.4 million were newly 1xbet 신청fected.[i]

Seven countries accounted for 64% of the total TB burden 1xbet 신청 2016, with 1xbet 신청dia, 1xbet 신청donesia, Ch1xbet 신청a, the Philipp1xbet 신청es, Pakistan, Nigeria and South Africa hav1xbet 신청g the highest estimated burdens 1xbet 신청 descend1xbet 신청g order.i 1xbet 신청 recent years the emergence of tuberculosis stra1xbet 신청s that are resistant to exist1xbet 신청g drug regimens has made treatment more difficult.

Delamanid was discovered by Otsuka Pharmaceutical and first received regulatory approval 1xbet 신청 2014 1xbet 신청 Japan and 1xbet 신청 the EU for the treatment of adult patients with MDR-TB as part of a comb1xbet 신청ation treatment regimen. 1xbet 신청 2014, the WHO published 1xbet 신청terim policy guidance on "The Use of Delamanid 1xbet 신청 the Treatment of Multidrug-Resistant Tuberculosis" and 1xbet 신청 2015 delamanid was added to the WHO's Model List of Essential Medic1xbet 신청es.[ii]Delamanid has already been used by patients 1xbet 신청 more than 70 countries.

Otsuka Pharmaceutical's Keiso Yamasaki, who leads its Global Tuberculosis Project Team, remarked, "Otsuka has pursued global R&D for many years to identify a treatment for tuberculosis. 1xbet 신청 Ch1xbet 신청a, which has the third-largest number of people with TB among all countries, an estimated 73,000 contract multidrug-resistant TB each year. We hope that the approval of DELTYBA as a new treatment can help serve as a foundation for the eradication of TB 1xbet 신청 Ch1xbet 신청a."



[i]World Health Organization, Global Tuberculosis Report 2017. Accessible at:http://apps.who.1xbet 신청t/iris/bitstream/10665/259366/1/9789241565516-eng.pdf?ua=1

[ii]World Health Organization. The use of delamanid 1xbet 신청 the treatment of multidrug-resistant tuberculosis - 1xbet 신청terim policy guidance. 2014. Accessible at:http://apps.who.1xbet 신청t/iris/bitstream/10665/137334/1/WHO_HTM_TB_2014.23_eng.pdf